LEADER 02173nam  2200553   450 
001 9910787566003321
005 20230803030757.0
010   $a1-78084-252-X
035   $a(CKB)2670000000399344
035   $a(EBL)1179622
035   $a(OCoLC)854971658
035   $a(SSID)ssj0001599916
035   $a(PQKBManifestationID)16306841
035   $a(PQKBTitleCode)TC0001599916
035   $a(PQKBWorkID)14892775
035   $a(PQKB)10283736
035   $a(MiAaPQ)EBC1179622
035   $a(Au-PeEL)EBL1179622
035   $a(EXLCZ)992670000000399344
100   $a20220517d2013      uy             0
101 0 $aeng
135   $aur|n|---|||||
181   $ctxt
182   $cc
183   $acr
200 00$aAdvances in the management of ankylosing spondylitis /$feditor, Andrei Calin
205   $a1st ed.
210  1$aLondon, England :$cFuture Medicine Ltd.,$d[2013]
210  4$dİ2013
215   $a1 online resource (121 p.)
300   $aDescription based upon print version of record.
311   $a1-78084-254-6 
327   $aTitle page; Copyright page; Contents; Foreword. Advances in the management of ankylosing spondylitis; 1. A brief history of ankylosing spondylitis; 2. Pathophysiology and symptoms; 3. Diagnosis of ankylosing spondylitis; 4. NSAIDs for spondyloarthrits including ankylosing spondylitis; 5. Targeted therapies: TNF-alpha blockers in the treatment of spondyloarthritides; 6. Targeted therapies: other agents; 7. Outcome measurements in ankylosing spondylitis; 8. Treatment algorithm and prognosis; Index
330   $aAdvances in the Management of Ankylosing Spondylitis
606   $aAnkylosing spondylitis$xTreatment
606   $aAnkylosing spondylitis$xChemotherapy
606   $aAnkylosing spondylitis
615  0$aAnkylosing spondylitis$xTreatment.
615  0$aAnkylosing spondylitis$xChemotherapy.
615  0$aAnkylosing spondylitis.
676   $a616.73
702   $aCalin$b Andrei
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910787566003321
996   $aAdvances in the management of ankylosing spondylitis$93846582
997   $aUNINA